Monitor European Commission decision expected in coming months; approval would add a new revenue stream via royalties from Zambon, with first sales likely in H2 2026. The event is positive but incremental given CREXONT already in US.
Price Chart
Executive Summary
Zambon and Amneal announced that the CHMP adopted a positive opinion recommending EU marketing authorization for Hopledo (IPX203), a modified-release levodopa/carbidopa for Parkinson's disease with motor fluctuations. If approved by the European Commission, Hopledo (already marketed as CREXONT in the US) could provide a new treatment option for over 1 million EU Parkinson's patients, with phased launch expected October 2026.
Key Facts
- CHMP positive opinion for Hopledo (IPX203) for EU approval.
- Hopledo is a modified-release levodopa/carbidopa for Parkinson's disease with moderate to severe motor fluctuations.
- Based on Phase 3 RISE-PD trial showing significantly more 'Good ON' time with fewer daily doses vs immediate-release levodopa/carbidopa.
- Already approved in the US as CREXONT; Zambon holds EU commercialization rights under a 2024 licensing agreement.
- If EC approves, phased launch across Europe expected to begin October 2026.
Financial Impact
No financial terms disclosed; potential incremental revenue from EU royalties/milestones starting late 2026.
Risk Factors
- European Commission may not follow CHMP recommendation.
- Commercial launch and market access could face delays or pricing pressures.
- Limited financial disclosure on Amneal's economic interest in EU sales.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3318687 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 23, 2026 4d ago | 8-K/A | $21.02 | awaiting T+60 | — | $21.44 (+2.00%) |
Sep 18, 2026 5w ago | Press Release | $20.16 | awaiting T+60 | — | $21.44 (+6.35%) |
Aug 16, 2026 10w ago | Institutional Cluster | $18.42 | awaiting T+60 | — | $21.44 (+16.40%) |
Aug 14, 2026 10w ago | Insider Cluster | $18.42 | awaiting T+60 | — | $21.44 (+16.40%) |
Aug 13, 2026 10w ago | Insider Cluster | $18.15 | awaiting T+60 | — | $21.44 (−18.13%) |
Aug 10, 2026 11w ago | 8-K | $17.10 | awaiting T+60 | — | $21.44 (+25.38%) |
Jul 30, 2026 12w ago | DEFA14A | $18.50 $20.38 | ▲ +10.16% | ▲ +7.70% | $21.44 (+15.89%) |
Jul 17, 2026 14w ago | Press Release | $17.85 $20.03 | ▲ +12.21% | ▲ +7.53% | $21.44 (+20.11%) |
Jun 29, 2026 17w ago | DEFM14A | $17.29 $19.50 | ▲ +12.78% | ▲ +8.40% | $21.44 (+24.00%) |
Jun 29, 2026 17w ago | Press Release | $17.29 $19.50 | ▲ +12.78% | ▲ +8.40% | $21.44 (+24.00%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers